Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value
By Nick Paul Taylor,
BioSpace
| 03. 14. 2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene autotemcel) when the Medicines and Healthcare products Regulatory Agency approved the treatment in November 2023. However, regulatory approval is just the first of two key steps to reaching patients in the U.K. Vertex must also show the therapy is cost-effective before it can be used routinely by the National Health Service (NHS).
The U.K. National Institute for Health and Care Excellence (NICE) recommended against the use of Casgevy in sickle cell disease in draft guidance. The therapy has a list price of $2.2 million in the U.S. but NICE’s guidance says the U.K. price is “commercial in confidence.” Vertex’s justification for the cost rests on the potential for a one-time treatment with Casgevy to provide a functional cure for sickle cell disease.
Currently, NICE’s cost-effectiveness estimate for Casgevy exceeds the threshold it normally views as a good use of the...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...